JP2005525391A - 認識維持の強化のためのスタチン治療 - Google Patents

認識維持の強化のためのスタチン治療 Download PDF

Info

Publication number
JP2005525391A
JP2005525391A JP2003579835A JP2003579835A JP2005525391A JP 2005525391 A JP2005525391 A JP 2005525391A JP 2003579835 A JP2003579835 A JP 2003579835A JP 2003579835 A JP2003579835 A JP 2003579835A JP 2005525391 A JP2005525391 A JP 2005525391A
Authority
JP
Japan
Prior art keywords
statin
galantamine
amount
dementia
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003579835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525391A5 (cg-RX-API-DMAC7.html
Inventor
リリエンフエルド,シーン
ガツターマン,エレーン・エム
グラスプール,ロイストン・ジヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of JP2005525391A publication Critical patent/JP2005525391A/ja
Publication of JP2005525391A5 publication Critical patent/JP2005525391A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2003579835A 2002-04-02 2003-03-28 認識維持の強化のためのスタチン治療 Pending JP2005525391A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Publications (2)

Publication Number Publication Date
JP2005525391A true JP2005525391A (ja) 2005-08-25
JP2005525391A5 JP2005525391A5 (cg-RX-API-DMAC7.html) 2006-01-26

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579835A Pending JP2005525391A (ja) 2002-04-02 2003-03-28 認識維持の強化のためのスタチン治療

Country Status (21)

Country Link
EP (1) EP1492539B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005525391A (cg-RX-API-DMAC7.html)
KR (1) KR100986194B1 (cg-RX-API-DMAC7.html)
CN (1) CN100528164C (cg-RX-API-DMAC7.html)
AT (1) ATE331523T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003226753B2 (cg-RX-API-DMAC7.html)
BR (1) BR0308293A (cg-RX-API-DMAC7.html)
CA (1) CA2480275C (cg-RX-API-DMAC7.html)
CY (1) CY1105545T1 (cg-RX-API-DMAC7.html)
DE (1) DE60306503T2 (cg-RX-API-DMAC7.html)
DK (1) DK1492539T3 (cg-RX-API-DMAC7.html)
EA (1) EA013069B1 (cg-RX-API-DMAC7.html)
ES (1) ES2268393T3 (cg-RX-API-DMAC7.html)
IL (2) IL164317A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04009535A (cg-RX-API-DMAC7.html)
NO (1) NO20044698L (cg-RX-API-DMAC7.html)
NZ (1) NZ536111A (cg-RX-API-DMAC7.html)
PL (1) PL211160B1 (cg-RX-API-DMAC7.html)
PT (1) PT1492539E (cg-RX-API-DMAC7.html)
UA (1) UA79605C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003082298A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP1737539A1 (en) * 2004-04-14 2007-01-03 Warner-Lambert Company LLC Therapeutic combination for treatment of alzheimers disease
EP1604686A1 (en) * 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
US20160303146A1 (en) * 2013-12-13 2016-10-20 David A. TABACZYNSKI Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Also Published As

Publication number Publication date
PL211160B1 (pl) 2012-04-30
CN100528164C (zh) 2009-08-19
PT1492539E (pt) 2006-11-30
KR100986194B1 (ko) 2010-10-07
DE60306503T2 (de) 2007-06-21
DK1492539T3 (da) 2006-10-30
PL371551A1 (en) 2005-06-27
CY1105545T1 (el) 2010-07-28
IL164317A0 (en) 2005-12-18
AU2003226753B2 (en) 2007-06-28
AU2003226753A1 (en) 2003-10-13
NZ536111A (en) 2006-03-31
NO20044698L (no) 2004-10-29
ATE331523T1 (de) 2006-07-15
EA200401295A1 (ru) 2005-02-24
DE60306503D1 (de) 2006-08-10
HK1079688A1 (zh) 2006-04-13
CN1642555A (zh) 2005-07-20
MXPA04009535A (es) 2005-01-25
EP1492539B1 (en) 2006-06-28
UA79605C2 (en) 2007-07-10
EP1492539A1 (en) 2005-01-05
ES2268393T3 (es) 2007-03-16
BR0308293A (pt) 2004-12-28
KR20040096608A (ko) 2004-11-16
IL164317A (en) 2010-04-29
EA013069B1 (ru) 2010-02-26
CA2480275C (en) 2011-08-16
WO2003082298A1 (en) 2003-10-09
CA2480275A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
US12496300B2 (en) Methods of treating acute depression and anxiety
Engin et al. Anxiolytic-and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models
TWI519299B (zh) 大麻素與抗精神病藥物組合使用之技術
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
JP2014074032A (ja) 嗜癖および鬱病を含むmgluレセプターに関連する疾患を処置するためのmgluレセプターアンタゴニスト
US20110034565A1 (en) Psycho-pharmaceuticals
US6835728B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
Messer The utility of muscarinic agonists in the treatment of Alzheimer’s disease
CA2480275C (en) Statin therapy for enhancing cognitive maintenance
JP2006176503A (ja) 脳血管障害を伴うアルツハイマー病治療薬
Tokita et al. Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats
Traub et al. The implication of current therapeutic approaches for the cholinergic hypothesis of dementia
CN114259486A (zh) 木犀草素及其药物组合物的应用
US20050222122A1 (en) Statin therapy for enhancing cognitive maintenance
CA3251657A1 (en) Trimeprazine is intended for use in the treatment of trigeminal neuralgia and to reduce the pain associated with it.
HK1079688B (en) Statin product for enhancing cognitive maintenance
EP1997486B1 (en) Therapeutic agent for functional brain disease
Wendling Pimavanserin shows promise in PD psychosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051125

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100309